(Q36235591)

12 August 2017

1 reference

title

Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity (English)

1 reference

12 August 2017

Manuel Hidalgo

2

0 references

Antonio Luiz Ribeiro

1 reference

ORCID Public Data File 2021

author name string

Antonio Jimeno

series ordinal

1

1 reference

12 August 2017

publication date

1 August 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

727-735

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

12 August 2017

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Signal transduction via the MAP kinases: proceed at your own RSK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

21 January 2018

The miracle of Iressa

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Epidermal growth factor receptor dependence in human tumors: more than just expression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Chemotherapy sensitivity and resistance assays: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.4.727

21 January 2018

Identifiers

DOI

10.1586/14737140.5.4.727

1 reference

12 August 2017

1 reference